系统性硬化症死亡原因图谱与预测模型
基于法国死亡证明与EUSTAR国际数据库共3700例死亡,分析系统性硬化症死因并建立预测评分。心脏与呼吸系统病因占主导,风险评分可准确预测3年死亡率(AUC 0.82)。
要点
- 心脏(27%-31%)与呼吸系统(17%-18%)是SSc主要死因
- 风险评分预测3年死亡率AUC为0.82,上四分位生存率53% vs 下四分位98%
- SSc特异性死亡率随时间增加
核心结论
- 心肺系统是SSc死亡的主要贡献者,风险评分可有效进行3年生存分层。
研究设计与样本
- 候选预后因素经Cox比例风险回归单变量分析后,行按中心分层的多变量模型,并采用bootstrapping进行内部验证。
主要发现
- 法国死亡证明中,心脏原因占31%,呼吸原因占18%,且SSc特异性死亡率随时间增加。
- EUSTAR队列中,死亡原因中心脏病占27%,呼吸原因占17%。
- 多变量分析建立的风险评分预测3年死亡率AUC为0.82;上四分位患者3年生存率53%,第一四分位为98%。
关键数值与推荐
- 风险评分预测3年死亡率AUC为0.82,上四分位3年生存率53%,第一四分位98%。
临床怎么用
- 临床可应用该风险评分对SSc患者进行风险分层,重点监测心肺受累以延长生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the causes of death and risk factors in systemic sclerosis (SSc). METHODS: Between 2000 and 2011, we examined the death certificates of all French patients with SSc to determine causes of death. Then we examined causes of death and developed a score associated with all-cause mortality from the international European Scleroderma Trials and Research (EUSTAR) database. Candidate prognostic factors were tested by Cox proportional hazards regression model by single variable analysis, followed by a multiple variable model stratified by centres. The bootstrapping technique was used for internal validation. RESULTS: We identified 2719 French certificates of deaths related to SSc, mainly from cardiac (31%) and respiratory (18%) causes, and an increase in SSc-specific mortality over time. Over a median follow-up of 2.3 years, 1072 (9.6%) of 11 193 patients from the EUSTAR sample died, from cardiac disease in 27% and respiratory causes in 17%. By multiple variable analysis, a risk score was developed, which accurately predicted the 3-year mortality, with an area under the curve of 0.82. The 3-year survival of patients in the upper quartile was 53%, in contrast with 98% in the first quartile. CONCLUSION: Combining two complementary and detailed databases enabled the collection of an unprecedented 3700 deaths, revealing the major contribution of the cardiopulmonary system to SSc mortality. We also developed a robust score to risk-stratify these patients and estimate their 3-year survival. With the emergence of new therapies, these important observations should help caregivers plan and refine the monitoring and management to prolong these patients' survival.
引用
- Elhai M, Meune C, Boubaya M, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017. PMID: 28835464. doi:10.1136/annrheumdis-2017-211448
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。